<span item_type="fundamental" item_id="29b5493539621c147defd83aa89c8bea" counter_id="ST/US/LTRN" env="prod"></span><span item_type="announcement" item_id="648851170905490561" env="prod"></span><p>EPS: As of FY2026 Q1, the actual value is USD -0.3, beating the estimate of USD -0.36.</p><p></p><h4>Net Loss</h4><p>Lantern Pharma Inc. reported a net loss of approximately - $3.3 million for the three months ended March 31, 2026, representing a 27% year-over-year reduction compared to a net loss of approximately - $4.5 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span></p><h4>Research and Development (R&amp;D) Expenses</h4><p>R&amp;D expenses were approximately $1.7 million for the three months ended March 31, 2026, marking a decrease of approximately $1.5 million or 47% from approximately $3.3 million for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span></p><h4>General and Administrative (G&amp;A) Expenses</h4><p>G&amp;A expenses increased by approximately $170,000 or 11% to approximately $1.7 million for the three months ended March 31, 2026, from approximately $1.5 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span></p><h4>Cash, Cash Equivalents, and Marketable Securities</h4><p>As of March 31, 2026, cash, cash equivalents, and marketable securities totaled approximately $6.3 million, down from approximately $10.1 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span></p><h4>Capitalization</h4><p>As of May 12, 2026, Lantern Pharma Inc. had 11,304,697 shares of common stock outstanding.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span></p><h4>Outlook and Guidance</h4><p>Lantern Pharma Inc. expects its pro forma liquidity, including approximately $4.4 million in gross proceeds from a May 14, 2026 financing, to fund operations into the middle of the first quarter of 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span> The company plans to host an investor webinar in the first half of June 2026 to detail the commercial trajectory and planned separation of its withZeta.ai platform into an independent business entity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span> Additionally, Lantern Pharma Inc. anticipates additional clinical data readouts from the Phase 2 HARMONIC™ trial in the second half of 2026 and the initiation of additional clinical trials for LP-184 and STAR-001 in 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm"></span></p>

Lantern Pharma | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.3